Boston Scientific (NYSE:[[ticker:BSX]]), the Natick, MA-based medical devices giant, reports that it has acquired drug-eluting stent developer Labcoat, headquartered in Galway, Ireland. Labcoat has developed technology to produce ultra-thin coatings of biodegradable polymers and drugs on the outer surface of coronary stents, which are designed to prop open arteries after surgeries to remove plaques. Financial terms of the deal weren’t disclosed.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
